Your shopping cart is currently empty

EGFR/AURKB-IN-1 (compound 7) serves as a dual inhibitor targeting EGFR/AURKB, effectively inhibiting the phosphorylations of L858R EGFR and AURKB with IC50 values of 0.07 and 1.1, respectively. The compound engages with the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB. This binding action suppresses tumor cell growth, division, and metastasis, making it a valuable agent for cancer research [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 4-6 weeks | 4-6 weeks | |
| 50 mg | $1,980 | 4-6 weeks | 4-6 weeks | |
| 100 mg | $2,500 | 4-6 weeks | 4-6 weeks |
| Description | EGFR/AURKB-IN-1 (compound 7) serves as a dual inhibitor targeting EGFR/AURKB, effectively inhibiting the phosphorylations of L858R EGFR and AURKB with IC50 values of 0.07 and 1.1, respectively. The compound engages with the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB. This binding action suppresses tumor cell growth, division, and metastasis, making it a valuable agent for cancer research [1]. |
| Molecular Weight | 396.44 |
| Formula | C23H20N6O |
| Cas No. | 3008543-34-5 |
| Smiles | N(C1=C2C(NC(=C2)C=3N(C)N=CC3)=NC=N1)C4=CC=C(OCC5=CC=CC=C5)C=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.